drugset / Trial / NCT01820767
Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients
RandomizedParallel-groupSingle-blindTreatment
Summary
Use of Paricalcitol in stage Vd Chronic Kidney Disease patients, over the effect of inflammatory and oxidative stress parameters.
Timeline
- Start
- 2012-08
- Primary completion
- 2013-10
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atorvastatin | Small molecule | 20 mg | Oral |
| Subject | Paricalcitol | Other / unclassified | — | Oral |